Hormonal
Retatrutide (LY3437943) administered subcutaneously once weekly produces significant, dose-dependent weight loss and improved glycaemic control in adults with obesity or type 2 diabetes, outperforming placebo and dulaglutide at higher doses (8-12 mg).
Retatrutide is a once-weekly injection that significantly reduces body weight (up to 26 kg in trials) and improves blood sugar control in people with obesity or type 2 diabetes. It works by targeting three hormone receptors (GIP, GLP-1, Glucagon). Higher doses (8-12 mg) are more effective but may cause mild gastrointestinal side effects that usually improve over time. It appears more effective than some existing treatments like dulaglutide for weight loss.
Retatrutide demonstrated dose-dependent reductions in body weight, with the highest doses (8 mg and 12 mg) achieving up to 26 kg weight loss. Improvements in glycaemic control, body mass index, waist circumference and lipid profiles were also observed. Higher doses yielded better results compared to placebo and dulaglutide.
Why this rating
Based on a systematic review of 4 clinical trials (Phase 1b and Phase 2), including RCTs, but limited by small sample sizes and heterogeneity preventing meta-analysis.
Source
Retatrutide (LY3437943) for metabolic disorders: A systematic review of clinical outcomes in obesity and type 2 diabetes
Shruti Singh et al. · Indian Journal of Physiology and Pharmacology · 2026
DOI 10.25259/ijpp_357_2025
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →